Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma
RegulatoryapprovedrocbrutinibPositive
AI Analysis
Summary
Lupeng Pharmaceutical announced accelerated approval of rocbrutinib (LP-168), a fourth-generation BTK inhibitor, from China's NMPA for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
Outcome Details
Accelerated approval granted by NMPA for rocbrutinib in relapsed or refractory mantle cell lymphoma
Importance:8/10
Sentiment:
0.85
BTK InhibitorChina ApprovalAccelerated ApprovalOncologyMantle Cell LymphomaNMPA
Read the original article
Published by PR Newswire Pharma on June 4, 2026 8:19 AM